Levothyroxine Sodium Tablets Recall by Accord Healthcare

Source: FDA · United States

Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.

Accord Healthcare Inc. is recalling certain lots of Levothyroxine Sodium Tablets, USP 200 mcg due to subpotent drug classification.

FDA recall: what the record actually shows

This notice was issued by FDA on September 7, 2026 and geographically references United States. The FDA classifies this as a Class II recall, with the stated reason "Subpotent Drug", distributed nationwide within the united states. FDA recall classes run from I (reasonable probability of serious harm) to III (unlikely to cause harm), so the class number is the fastest way to gauge severity here. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.

A quick skim tells you whether this affects you directly; a closer read tells you more. Check the scope, the source, and how recent the record is, then weigh it against related notices rather than treating any single one as a trend.

Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, Drugs.

What Happened

Accord Healthcare, Inc. initiated a voluntary recall of Levothyroxine Sodium Tablets, USP, 200 mcg (0.2 mg) classified as Class II by the FDA for subpotent drug.

Which Products Are Affected

The recall affects Levothyroxine Sodium Tablets, USP, 200 mcg (0.2 mg) packaged in a) 90-count bottles (NDC 16729-457-15) and b) 1000-count bottles (NDC 16729-457-17). Affected lots include a) Lot # D2402430, D2402431 (Exp. 10/31/2026) and b) Lot # D2402432 (Exp. 10/31/2026), D2500180 (Exp. 12/31/2026). The products were distributed nationwide within the United States. Recall number D-0785-2026.

What You Should Do

Consumers with questions should contact the recalling firm, Accord Healthcare, Inc.

Why This Matters

This Class II recall involves a subpotent drug distributed nationwide.

Source

FDA recall D-0785-2026 - Accord Healthcare, Inc., Raleigh, NC.

Original source: FDA Official Notice ↗

All FDA Recalls →

Similar notices nationwide by length or severity timing 8

Two Areazine-derived peer sets for this FDA recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.

Common Questions

Questions readers often have about this FDA recall.

What is this FDA recall about? ▾
Accord Healthcare Inc. is recalling certain lots of Levothyroxine Sodium Tablets, USP 200 mcg due to subpotent drug classification.
Which agency issued this alert? ▾
This alert was issued by FDA. The original notice is available at the source link at the bottom of this article.
How is this recall classified, and why does that matter? ▾
The FDA classifies this as a Class II recall, citing "Subpotent Drug" as the reason. Class I is the most serious (reasonable probability of serious harm), Class II is a moderate or temporary health risk, and Class III is unlikely to cause harm.
What area is affected? ▾
This alert affects United States. Check with FDA for the most current geographic scope.
Where can I find more FDA Recalls updates? ▾
Browse the full FDA Recalls feed on Areazine at areazine.com/recalls/fda/ for the latest updates from FDA and other agencies.